Basilea Pharmaceutica Ownership
| BSLN Stock | CHF 40.90 0.05 0.12% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Basilea |
Basilea Stock Ownership Analysis
About 29.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 190.88. Basilea Pharmaceutica last dividend was issued on the 11th of April 2013. The entity had 1039:1029 split on the 13th of March 2007. Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA N operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange. It employs 160 people. For more info on Basilea Pharmaceutica AG please contact the company at 41 61 606 11 11 or go to https://www.basilea.com.Basilea Pharmaceutica Outstanding Bonds
Basilea Pharmaceutica issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Basilea Pharmaceutica uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Basilea bonds can be classified according to their maturity, which is the date when Basilea Pharmaceutica AG has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Basilea Stock Analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.